Correction (DOI:10.1016/j.curtheres.2007.12.002);Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada)

Current Therapeutic Research - Clinical and Experimental

Volumn 68, Issue 6, 2007, Pages 409-420

  Ganesan, Soma ^a,b,c   McKenna, Mario ^b   Procyshyn, Ric M ^a,d   Zipursky, Sheldon ^a,b,e,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Vancouver Community Mental Health Services   (Canada)

^d RIVERVIEW HOSPITAL   (Canada)

^e Richmond Hospital   (Canada)

^f Richmond Health Services   (Canada)

Author keywords

atypical antipsychotics; hospitalization; relapse; risperidone long acting injection; schizophrenia

Indexed keywords

LONG ACTING DRUG; LOXAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AFRICAN AMERICAN; AKATHISIA; AMERICAN INDIAN; ARTICLE; ASIAN; CANADA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; EUROPEAN AMERICAN; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMPOTENCE; LENGTH OF STAY; MALE; MEDICAL RECORD; MENTAL PATIENT; OUTPATIENT; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT;

EID: 38049078311     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.02.008     Document Type: Erratum

References (45)

1. Goldner E., Hsu L., Waraich P., and Somers J. Prevalence and incidence studies of schizophrenic disorders: A systematic review of the literature. Can J Psychiatry 47 (2002) 833-843
2. Lambert T., and Castle D. Pharmacological approaches to the management of schizo-phrenia. Med J Aust 178 Suppl (2003) S57-S61
3. Schizophrenia W.R. A 100-year retrospective. Am J Psychiatry 152 (1995) 1693 author reply 1694-1695
4. The Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 43 Suppl 2 (1998) 25S-40S
5. Goeree R., O'Brien B., Goering P., et al. The economic burden of schizophrenia in Canada. Can J Psychiatry 44 (1999) 464-472
6. Chue P., Devos E., Duchesne I., et al. One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting intramuscular risperidone. Schizophr Res 60 Suppl 1 (2003) 277-278
7. Strasser O., Schmauss M., and Messer T. Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication [in German ]. Psychiatr Prax 31 Suppl 1 (2004) S38-S40
8. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 407 (2000) 15-18
9. Davies L., and Drummond M. Economics and schizophrenia: The real cost. Br J Psychiatry Suppl. 22 (1994) 18-21
10. Foster R., and Goa K. Risperidone. A pharmacoeconomic review of its use in schizo-phrenia. Pharmacoeconomics 14 (1998) 97-133
11. Beasley Jr. C., Sutton V., Hamilton S., et al., Olanzapine Relapse Prevention Study Group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 22 (2003) 582-594
12. Robinson D., Woerner M., Alvir J., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156 (1999) 544-549
13. Weiden P., and Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 21 (1995) 419-429
14. Hogarty G., and Ulrich R. The limitations of antipsychotic medication on schizo-phrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 32 (1998) 243-250
15. Fenton W., Blyler C., and Heinssen R. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull. 22 (1997) 637-651
16. Essock S., Hargreaves W., Covell N., and Goethe J. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull 32 (1996) 683-697
17. Hogarty G. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 54 Suppl (1993) 18-23
18. Davis J., and Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64 Suppl 16 (2003) 22-33
19. Glick I., and Berg P. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 17 (2002) 65-68
20. Kane J. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: Clinical studies. J Clin Psychiatry 64 Suppl 16 (2003) 33-40
21. Kane J., Leucht S., Carpenter D., Docherty J., and Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 64 Suppl 12 (2003) 5-19
22. Liu-Seifert H., Adams D., and Kinon B. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 3 (2005) 22
23. Ereshefsky L., and Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: Potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 6 (2005) 129-137
24. Janssen-Ortho Inc. Product Monograph Risperdal® Consta®. http://www.janssenortho.com/JOI/pdf_files/Risperdal_E.pdf. Accessed November 20, 2007.
25. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (1976), Md: National Institute of Mental Health, Rockville 218-222 (DHEW Publ No ADM 76-338)
26. Csernansky J., Mahmoud R., Brenner R., and Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [published correction appears in N Engl J Med.2002;33:1424]. N Engl J Med 346 (2002) 16-22
27. Desai N., Huq Z., Martin S., McDonald G., and Schizophrenia Treatment & Assessment Group. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. Adv Ther 16 (1999) 78-88
28. Fleischhacker W., Eerdekens M., Karcher K., et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64 (2003) 1250-1257
29. Kane J., Eerdekens M., Lindenmayer J., et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160 (2003) 1125-1132
30. Lasser R., Bossie C., Gharabawi G., and Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 19 (2004) 219-225
31. Love R., and Conley R. Long-acting risperidone injection. Am J Health Syst Pharm 61 (2004) 1792-1800
32. Marder S., and Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry 151 (1994) 825-835
33. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. http://www.emea.eu.int. Accessed December 13, 2006.
34. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Website ]. Ferney-Voltaire, France: WMA; 1989. http://www.wma.net. Accessed December 13, 2006.
35. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. Fourth Edition (1994), APA, Washington, DC
36. Kissling W., Heres S., Lloyd K., et al. Direct transition to long-acting risperidone analysis of long-term efficacy. J Psychopharmacol. 19 Suppl 5 (2005) 15-21
37. Lauriello J., McEvoy J., Rodriguez S., et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res. 72 (2005) 249-258
38. Lee M., Ko Y., Lee S., et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol. 22 (2006) 339-407
39. Martin S., Libretto S., Pratt D., et al. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin. 11 (2003) 298-305
40. Mohl A., Westlye K., Opjordsmoen S., et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 19 Suppl 5 (2005) 22-31
41. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin. 22 (2006) 241-255
42. Simpson G., Mahmoud R., Lasser R., et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67 (2006) 1194-1203
43. Turner M., Eerdekens E., Jacko M., and Eerdekens M. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 19 (2004) 241-249
44. Knox E., and Stimmel G. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther. 22 (2004) 1994-2002
45. Moller H. Long-acting risperidone: Focus on safety. Clin Ther 28 (2006) 633-651